These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10236705)

  • 1. Protecting the "animal of necessity": limits to inquiry in clinical investigation.
    Swazey JP
    Daedalus; 1978; ():129-45. PubMed ID: 10236705
    [No Abstract]   [Full Text] [Related]  

  • 2. Lay participation in medical policy making. II. Human experimentation committees: professional or representative?
    Veatch RM
    Hastings Cent Rep; 1975 Oct; 5(5):31-40. PubMed ID: 1184371
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ethical principles in preclinical and clinical experimentation on new drugs, with special reference to biological products].
    Pérez Miravete A
    Salud Publica Mex; 1986; 28(4):443-56. PubMed ID: 3775534
    [No Abstract]   [Full Text] [Related]  

  • 4. Protecting the "animal of necessity": limits to inquiry in clinical investigation.
    Swazey JP
    Daedalus; 1978; 107(2):129-45. PubMed ID: 11645787
    [No Abstract]   [Full Text] [Related]  

  • 5. Protecting research subjects--what must be done.
    Shalala D
    N Engl J Med; 2000 Sep; 343(11):808-10. PubMed ID: 10984573
    [No Abstract]   [Full Text] [Related]  

  • 6. Making clinical trials safer for human subjects.
    Baram M
    Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulating human gene therapy: legislative overreaction to human subject protection failures.
    Leavitt WJ
    Adm Law Rev; 2001; 53(1):315-41. PubMed ID: 16189905
    [No Abstract]   [Full Text] [Related]  

  • 8. The standard of disclosure in human subject experimentation.
    Morin K
    J Leg Med; 1998 Jun; 19(2):157-221. PubMed ID: 9658739
    [No Abstract]   [Full Text] [Related]  

  • 9. Protecting research subjects--the crisis at Johns Hopkins.
    Steinbrook R
    N Engl J Med; 2002 Feb; 346(9):716-20. PubMed ID: 11870258
    [No Abstract]   [Full Text] [Related]  

  • 10. [Importance of local review committees (institutional review boards) for the protection of experimental subjects].
    Rickels K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1978; 19():94-112. PubMed ID: 714042
    [No Abstract]   [Full Text] [Related]  

  • 11. On parallel tracts: protecting human subjects and animals.
    Mishkin B
    Hastings Cent Rep; 1985 Oct; 15(5):36-7. PubMed ID: 3840780
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug evaluation problems in academic and other contexts.
    Lasagna L
    Ann N Y Acad Sci; 1970 Jan; 169(2):503-8. PubMed ID: 4907496
    [No Abstract]   [Full Text] [Related]  

  • 13. Federal report says protection of human subjects is threatened by numerous factors.
    Maloney DM
    Hum Res Rep; 1996 May; 11(5):1-3. PubMed ID: 11654438
    [No Abstract]   [Full Text] [Related]  

  • 14. The freedom of medical information.
    Brody EB
    JAMA; 1975 Jul; 233(2):145-6. PubMed ID: 1173440
    [No Abstract]   [Full Text] [Related]  

  • 15. Research compliance changes will affect rules on protection of human subjects.
    Maloney DM
    Hum Res Rep; 1999 May; 14(5):1-2. PubMed ID: 11657776
    [No Abstract]   [Full Text] [Related]  

  • 16. Federal investigation concludes that institutional review boards are in trouble.
    Maloney DM
    Hum Res Rep; 1998 Aug; 13(8):1-2. PubMed ID: 11657190
    [No Abstract]   [Full Text] [Related]  

  • 17. Agencies said to be slow on research protections reform.
    Maloney DM
    Hum Res Rep; 2001 Jul; 16(7):3. PubMed ID: 11933954
    [No Abstract]   [Full Text] [Related]  

  • 18. MBD, drug research and the schools. A Conference on Medical Responsibility and Community Control/February 13-14, 1976.
    Hastings Cent Rep; 1976 Jun; 6(3):suppl 1-23. PubMed ID: 955873
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethical implications of withdrawal of experimental drugs at the conclusion of phase III trials.
    Roginsky MS; Handley A
    Clin Res; 1978 Dec; 26(6):384-8. PubMed ID: 10239695
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection of human rights in medical research.
    Can Med Assoc J; 1969 Aug; 101(4):237-8. PubMed ID: 5820363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.